Bausch + Lomb (NYSE:BLCO) Price Target Lowered to $18.00 at Stifel Nicolaus

Bausch + Lomb (NYSE:BLCO - Free Report) had its target price trimmed by Stifel Nicolaus from $19.00 to $18.00 in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a hold rating on the stock.

A number of other research analysts also recently issued reports on the stock. Citigroup downgraded shares of Bausch + Lomb from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $24.00 to $22.00 in a research report on Wednesday, December 11th. Evercore ISI raised shares of Bausch + Lomb from an "in-line" rating to an "outperform" rating and increased their price target for the stock from $19.00 to $25.00 in a research note on Tuesday, October 15th. Royal Bank of Canada lifted their price objective on Bausch + Lomb from $20.00 to $23.00 and gave the company an "outperform" rating in a research report on Tuesday, October 22nd. HC Wainwright reissued a "buy" rating and issued a $23.00 target price on shares of Bausch + Lomb in a research report on Thursday, December 12th. Finally, Morgan Stanley lowered Bausch + Lomb from an "overweight" rating to an "equal weight" rating and set a $19.00 price target on the stock. in a research report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $20.25.

Bausch + Lomb Trading Down 1.7 %

Shares of NYSE BLCO traded down $0.31 during trading hours on Wednesday, hitting $17.34. The company's stock had a trading volume of 361,976 shares, compared to its average volume of 525,870. The business has a 50-day simple moving average of $18.29 and a 200-day simple moving average of $18.15. The stock has a market cap of $6.11 billion, a price-to-earnings ratio of -16.52, a P/E/G ratio of 2.37 and a beta of 0.47. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. Bausch + Lomb has a 12 month low of $13.16 and a 12 month high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.01. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period last year, the company earned $0.22 EPS. The business's quarterly revenue was up 18.8% compared to the same quarter last year. On average, analysts anticipate that Bausch + Lomb will post 0.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bausch + Lomb

Several large investors have recently modified their holdings of the stock. Blue Trust Inc. increased its stake in Bausch + Lomb by 68.3% during the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock valued at $48,000 after purchasing an additional 1,004 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of Bausch + Lomb during the fourth quarter valued at approximately $72,000. Squarepoint Ops LLC bought a new stake in shares of Bausch + Lomb during the second quarter valued at approximately $173,000. Gordian Capital Singapore Pte Ltd purchased a new position in Bausch + Lomb in the 3rd quarter worth approximately $289,000. Finally, Polar Asset Management Partners Inc. bought a new position in Bausch + Lomb in the 3rd quarter valued at approximately $289,000. Hedge funds and other institutional investors own 11.07% of the company's stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.